Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
NORADRENALINE MYLAN (Alphapharm Pty Ltd)
Product name
NORADRENALINE MYLAN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
166 (255 working days)
Active ingredients
noradrenaline (norepinephrine) acid tartrate monohydrate
Registration type
New generic medicine
Indication
NORADRENALINE MYLAN (concentrated injection) is indicated for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).
As an adjunct in the treatment of cardiac arrest. To restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.